National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov
In English | En español
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

BI 2536
A small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:betulinic acid, bevacizumab, bexarotene, Bextra, Bexxar
Next:Biaxin, BIBX 1382, bicalutamide, Bicitra, BiCNU

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov